Literature DB >> 12673182

Myocardial kinetics of Tc-99m glucarate in low flow, hypoxia, and aglycemia.

D R Okada1, G Johnson, Z Liu, S D Hocherman, B A Khaw, K Y Pak, R D Okada.   

Abstract

BACKGROUND: Technetium-99m glucarate is a myocardial infarct-avid imaging agent. Recent conflicting and inconclusive reports have suggested that the agent may be taken up by ischemic but viable myocardium. The purposes of this study were (1) to determine conclusively whether there is Tc-99m glucarate uptake in ischemic viable myocardium and (2) to investigate the potential mechanisms for such uptake by studying components of ischemia, namely, low flow, hypoxia, and aglycemia. METHODS AND
RESULTS: Rat hearts were isolated and perfused in a modified Langendorff preparation with a crytalloid perfusate. Tc-99m glucarate was studied in control (n = 6), low-flow (n = 5), hypoxic (n = 5), and aglycemic (n = 5) conditions. The experimental protocol consisted of 20-minute baseline (12 mL/min flow) and 20-minute treatment (low flow at 1 mL/min, hypoxia, or aglycemia), followed by tracer uptake (20 minute) and washout (20 minutes). Activity was monitored with a sodium iodide detector. The tracer was delivered continuously over a 20-minute uptake period. The injected dose was 150 micro Ci (5.6 MBq). Hemodynamics were monitored throughout. Triphenyltetrazolium chloride staining was used to assess myocardial viability. There was no evidence of myocardial necrosis. Low flow tended to delay tracer uptake compared with control for the first 10 minutes, but this did not reach statistical significance. Low flow increased end fractional retention significantly compared with control (mean +/- SEM, 59.0% +/- 0.9% peak vs 41.2% +/- 1.4%, respectively; P <.05). Hypoxia resulted in a trend toward increased uptake; however, this was significant only at one early time point during the uptake phase. Retention in the hypoxia group was similar to control. Tc-99m glucarate uptake was significantly increased in aglycemia from 16 minutes to peak compared with control (1.36% +/- 0.71% injected dose per gram vs 0.91% +/- 0.37% injected dose per gram, respectively; P <.05). Aglycemia produced significantly higher end fractional retention compared with control (51.6% +/- 1.8% peak vs 41.2% +/- 1.4%, respectively; P <.05).
CONCLUSIONS: Tc-99m glucarate myocardial retention is increased in the setting of ischemia, even in the absence of necrosis. This increased retention is not due to hypoxia. Furthermore, the retention is only partially explained by tissue hypoglycemia. Thus low flow per se appears to have a role in this increased retention, probably as a result of delayed flow-dependent washout.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12673182     DOI: 10.1067/mnc.2003.1

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  17 in total

1.  Avidity of technetium 99m glucarate for the necrotic myocardium: in vivo and in vitro assessment.

Authors:  B A Khaw; A Nakazawa; S M O'Donnell; K Y Pak; J Narula
Journal:  J Nucl Cardiol       Date:  1997 Jul-Aug       Impact factor: 5.952

2.  Histochemical and fluorescent techniques for detection of early myocardial ischemia following experimental coronary artery occlusion: a comparative and quantitative study.

Authors:  P Chopra; U Sabherwal
Journal:  Angiology       Date:  1988-02       Impact factor: 3.619

3.  99mTc-HL91. Effects of low flow and hypoxia on a new ischemia-avid myocardial imaging agent.

Authors:  R D Okada; G Johnson; K N Nguyen; B Edwards; C M Archer; J D Kelly
Journal:  Circulation       Date:  1997-04-01       Impact factor: 29.690

4.  A new method for radionuclide imaging of myocardial infarcts.

Authors:  F J Bonte; R W Parkey; K D Graham; J Moore; E M Stokely
Journal:  Radiology       Date:  1974-02       Impact factor: 11.105

5.  Angiotensin II reduces infarct size and has no effect on post-ischaemic contractile dysfunction in isolated rat hearts.

Authors:  W R Ford; A S Clanachan; C R Hiley; B I Jugdutt
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

6.  Technetium-99m glucarate uptake in a swine model of limited flow plus increased demand.

Authors:  L L Johnson; L Schofield; P Mastrofrancesco; T Donahay; A Farb; B A Khaw
Journal:  J Nucl Cardiol       Date:  2000 Nov-Dec       Impact factor: 5.952

7.  Localization of technetium-99m-glucarate in zones of acute cerebral injury.

Authors:  H Yaoita; T Uehara; A L Brownell; C A Rabito; M Ahmad; B A Khaw; A J Fischman; H W Strauss
Journal:  J Nucl Med       Date:  1991-02       Impact factor: 10.057

8.  Distribution of deoxyglucose and technetium-99m-glucarate in the acutely ischemic myocardium.

Authors:  H Yaoita; A J Fischman; R Wilkinson; B A Khaw; M Juweid; H W Strauss
Journal:  J Nucl Med       Date:  1993-08       Impact factor: 10.057

9.  Comparison of technetium-99m-glucarate and thallium-201 for the identification of acute myocardial infarction in rats.

Authors:  H Ohtani; R J Callahan; B A Khaw; A J Fishman; R A Wilkinson; H W Strauss
Journal:  J Nucl Med       Date:  1992-11       Impact factor: 10.057

10.  Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid.

Authors:  C Orlandi; P D Crane; D S Edwards; S H Platts; L Bernard; J Lazewatsky; M J Thoolen
Journal:  J Nucl Med       Date:  1991-02       Impact factor: 10.057

View more
  5 in total

1.  99mTc-glucarate kinetics differentiate normal, stunned, hibernating, and nonviable myocardium in a perfused rat heart model.

Authors:  David R Okada; Zhonglin Liu; Gerald Johnson; Delia Beju; Ban An Khaw; Robert D Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-24       Impact factor: 9.236

2.  (99m)Tc-glucarate imaging for the early detection of infarct in partially reperfused canine myocardium.

Authors:  Gerald Johnson; Christine C Okada; Sonia D Hocherman; Zhonglin Liu; Curtis Hart; Ban-An Khaw; Robert D Okada
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-20       Impact factor: 9.236

3.  Could 99mTc-glucarate be used to evaluate tumour necrosis? In vitro and in vivo studies in leukaemic tumour cell line U937.

Authors:  Nathalie Perek; Odile Sabido; Nathalie Le Jeune; Nathalie Prevot; Jean-Michel Vergnon; Anthony Clotagatide; Francis Dubois
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

Review 4.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

5.  The Contractility of Isolated Rat Atrial Tissue during Hypoxia is Better Preserved in a High- or Zero-Glucose Environment than in a Normal Glucose Environment.

Authors:  Zoltán Szabó; Kristofer Katkits; George Gabro; Rolf Gg Andersson
Journal:  Int J Biomed Sci       Date:  2009-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.